Most Read Articles
4 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

2 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
4 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
The risk factors and outcomes associated with an increased risk of permanent pacing include atrial fibrillation (AF) ablation, multivalve surgery and New York Heart Association (NYHA) functional class III/IV, a recent study has found.

Rituximab a promising option in JIA patients failing other therapies

24 Nov 2018

Rituximab appears to be effective in the treatment of children with juvenile idiopathic arthritis (JIA) who have not responded to a tumour necrosis factor inhibitor (TNFi), a study has shown. Moreover, serious infection rates are low.

The present analysis included a real-world cohort of 41 JIA patients within the UK Biologics for Children with Rheumatic Diseases study initiating rituximab. Assessments included disease activity (at baseline and follow-up), the total number of courses each patient received, and serious infections and infusion reactions following treatment.

The median age of the cohort was 15 years, and 80 percent were female. Most of the patients had polyarthritis—rheumatoid factor (RF)-negative polyarthritis (35 percent), RF-positive polyarthritis (33 percent) or extended oligoarthritis (23 percent)—with a median disease duration of 9 years.

From rituximab initiation, the clinical Juvenile Arthritis Disease Activity Score (cJADAS; three-variable 71-joint JADAS) improved by a median of 9 units (IQR, −14 to 2; n=7). More than half of the patients received more than one course of treatment: 17 (41 percent) had one, 12 (29 percent) had two, seven (17 percent) had three, and five (12 percent) had four or more. The median time between each treatment course was 219 days (IQR, 198–315).

During follow-up, 17 patients (41 percent) reported switching to another biologic, including tocilizumab (n=8), abatacept (n=6) and TNFi (n=3).

In terms of safety, three patients (7 percent) developed a serious infection on rituximab, yielding a first serious infection rate of 6.2 per 100 person-years. There were four patients (10 percent) who had an infusion reaction.

The present data, although reassuring, highlight a need for a clinical trial of rituximab to establish clear efficacy and safety in patients with JIA, as well as to identify in which International League of Associations for Rheumatology (ILAR) categories the drug may be most effective, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

2 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
4 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
The risk factors and outcomes associated with an increased risk of permanent pacing include atrial fibrillation (AF) ablation, multivalve surgery and New York Heart Association (NYHA) functional class III/IV, a recent study has found.